Contego Medical Names Dr. Mitchell J. Silver as Chief Medical Officer

August 5, 2024—Contego Medical, Inc. announced that Mitchell J. Silver, DO, has joined the company as Chief Medical Officer (CMO). He will play a pivotal role in shaping the company’s clinical strategy and advancing the portfolio of carotid and thrombectomy products, stated the company.

Dr. Silver is an interventional cardiologist and vascular medicine specialist who previously served as the Director of the Center for Critical Limb Care and Endovascular Research at OhioHealth Heart and Vascular Physicians in Columbus, Ohio. Dr. Silver founded the Cornwell Center for Cardiovascular and Diabetes Care at Ohio University.

Contego Medical stated that Dr. Silver’s contributions to the field include more than 100 peer-reviewed manuscripts and book chapters on carotid artery atherosclerosis, peripheral vascular disease, and venous thromboembolism. He has been a proponent of carotid artery stenting since the 1990s and contributed to research efforts to develop the first embolic protection device.

The company noted that Dr. Silver’s collaboration with Contego Medical dates back to the company’s inception, including serving on the company’s board.

“Dr. Silver is a visionary in the cardiovascular space,” commented Contego Medical’s CEO and Founder Ravish Sachar, MD, in the company’s press release. “He has been deeply involved in the treatment of carotid and peripheral vascular disease for many years, and his experience and dedication to advancing medical research prepared him to make a significant impact here. He is uniquely suited for the role of Contego’s CMO, and we are very excited and honored that he will be joining Contego full time.”

According to the Contego Medical, Dr. Silver will help guide clinical development, regulatory affairs, and commercialization efforts for the upcoming launch of the Neuroguard integrated embolic protection (IEP) system carotid stent delivery catheter, Neuroguard IEP Direct transcarotid revascularization system, and Excipio peripheral thrombectomy devices.

In the United States, the Neuroguard IEP system is currently limited by Federal law to investigational use only in the PERFORMANCE II study. The Neuroguard IEP Direct system is currently limited by Federal law to investigational use only in the PERFORMANCE III.